Suvorexant (MK-4305) , ≥98% , 1030377-33-3

CAS NO.：1030377-33-3

Empirical Formula: C23H23ClN6O2

Molecular Weight: 450.92

MDL number: MFCD22377755

EINECS: 685-109-7

PRODUCT Properties

• Melting point: 153℃
• Boiling point: 669.8±65.0 °C(Predicted)
• Density: 1.41
• storage temp.: Room Temperature
• solubility: Acetonitrile (Slightly), Chloroform (Slightly), DMSO (Slightly, Heated)
• form: Solid
• pka: 1.47±0.40(Predicted)
• color: White to Pale Beige
• InChIKey: JYTNQNCOQXFQPK-MRXNPFEDSA-N
• SMILES: C(N1[C@H](C)CCN(C2=NC3=CC(Cl)=CC=C3O2)CC1)(C1=CC(C)=CC=C1N1N=CC=N1)=O

Description and Uses

Suvorexant, a dual orexin receptor antagonist marketed under the trade name Belsomra®, discovered and developed by Merck for the treatment of insomnia, was approved by the US FDA in August 2014 and became available in Japan in November of the same year. The drug’s mechanism of action operates through the competitive blockade of wake-promoting neuropeptides orexin A and orexin B toward receptors orexin receptor type 1 and orexin receptor type 2, which are believed to modulate sleep-wake cycles.

Suvorexant (MK-4305) is a dual (non-selective) orexin receptor antagonist in development by Merck & Co. for the treatment of insomnia. It works by turning off wakefulness rather than by inducing sleep. Users of higher doses had an increased rate of suicidal ideation.

Safety

• Symbol(GHS): GHS07,GHS08,GHS09
• Signal word: Warning
• Hazard statements: H410-H336-H400-H373
• Precautionary statements: P273-P391-P501-P260-P314-P501-P273-P391-P501-P261-P271-P304+P340-P312-P403+P233-P405-P501
• DEA Controlled Substances: CSCN: 2223; CAS SCH: IV ; NARC: N